Center For Scientific Review; Notice of Closed Meetings, 57833-57834 [2015-24320]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 186 / Friday, September 25, 2015 / Notices
Upon the expiration or termination of
the Start-up Exclusive Evaluation
Option License Agreement, Angio360
Diagnostics, LLC will have the exclusive
right to execute a Start-Up Exclusive
Patent License Agreement which will
supersede and replace the Start-up
Exclusive Evaluation Option License
Agreement, with no greater field of use
and territory than granted in the Startup Exclusive Evaluation Option License
Agreement.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
October 13, 2015 will be considered.
ADDRESSES: Requests for copies of the
patent application(s), inquiries,
comments, and other materials relating
to the contemplated Start-Up Exclusive
Evaluation Option License Agreement
should be directed to: Rose M. Freel,
Licensing and Patenting Manager, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 402–
9521; Facsimile: (301) 402–0220; Email:
rose.freel@nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
Patent and Trademark Office or the
World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: This
technology describes a method of
detecting pathological angiogenesis
(formation of new blood vessels) using
the expression levels of certain proteins
for the diagnosis of cancer or monitoring
response to cancer treatment.
The prospective Start-Up Exclusive
Evaluation Option License Agreement is
being considered under the small
business initiative launched on October
1, 2011 and will comply with the terms
and conditions of 35 U.S.C. 209 and 37
CFR part 404. The prospective Start-Up
Exclusive Evaluation Option License
Agreement and a subsequent Start-Up
Exclusive Patent License Agreement
may be granted unless the NIH receives
written evidence and argument, within
fifteen (15) days from the date of this
published notice, that establishes that
the grant of the contemplated Start-Up
Exclusive Evaluation Option License
Agreement would not be consistent with
the requirements of 35 U.S.C. 209 and
37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-Up Exclusive
VerDate Sep<11>2014
19:58 Sep 24, 2015
Jkt 235001
Evaluation Option License Agreement.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: September 21, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–24331 Filed 9–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cell Biology.
Date: October 14, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: John Burch, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 3213,
MSC 7808, Bethesda, MD 20892, 301–408–
9519, burchjb@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Clinical Oncology Study Section.
Date: October 19, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Reston Hotel, 11810
Sunrise Valley Drive, Reston, VA 20191.
Contact Person: Malaya Chatterjee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
57833
Health, 6701 Rockledge Drive, Room 6192,
MSC 7804, Bethesda, MD 20892, 301–806–
2515, chatterm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cancer,
Cardiovascular and Sleep Epidemiology
Panel B Study Section.
Date: October 19–20, 2015.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue NW., Washington, DC 20037.
Contact Person: Ellen K. Schwartz, EDD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3144,
MSC 7770, Bethesda, MD 20892, 301–828–
6146, schwarel@mail.nih.gov.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Virology—A Study Section.
Date: October 26–27, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Washington DC,
Dupont Circle, 1143 New Hampshire Avenue
NW., Washington, DC 20037.
Contact Person: Kenneth M. Izumi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3204,
MSC 7808, Bethesda, MD 20892, 301–496–
6980, izumikm@csr.nih.gov.
Name of Committee: Immunology
Integrated Review Group; Innate Immunity
and Inflammation Study Section.
Date: October 29–30, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Alexandria-Old
Town, 1900 Diagonal Road, Alexandria, VA
22314.
Contact Person: Tina McIntyre, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4202,
MSC 7812, Bethesda, MD 20892, 301–594–
6375, mcintyrt@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Special
Topic: Development Functions and Immune
Mediated Diseases.
Date: October 30, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Capital View, 2850
South Potomac Avenue, Arlington, VA
22202.
Contact Person: Deborah Hodge, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4207
MSC 7812, Bethesda, MD 20892, (301) 435–
1238, hodged@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PARs:
Developing and Testing Interventions for
Health-Enhancing Physical Activity.
Date: October 30, 2015.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\25SEN1.SGM
25SEN1
57834
Federal Register / Vol. 80, No. 186 / Friday, September 25, 2015 / Notices
Place: The Fairmont Washington, DC, 2401
M Street NW., Washington, DC 20037.
Contact Person: Weijia Ni, Ph.D., Chief/
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3100,
MSC 7808, Bethesda, MD 20892, (301) 594–
3292, niw@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Infection,
Complement Activation and Inflammatory
Immune Tolerance.
Date: October 30, 2015.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Bahiru Gametchu, DVM,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4204,
MSC 7812, Bethesda, MD 20892, 301–435–
1225, gametchb@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 21, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–24320 Filed 9–24–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Closed Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Name of Committee: National Cancer
Institute Special Emphasis Panel; Processes
in Cancer Control.
Date: October 14, 2015.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
Jkt 235001
Name of Committee: National Cancer
Institute Special Emphasis Panel; Omnibus
R03 & R21/SEP–5.
Date: November 19–20, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Salon G, Gaithersburg, MD 20878.
Contact Person: Thomas A. Winters, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W412, Bethesda, MD
20892–9750, 240–276–6386, twinters@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
[FR Doc. 2015–24321 Filed 9–24–15; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
19:58 Sep 24, 2015
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Dated: September 21, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
VerDate Sep<11>2014
2E904, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Gerald G. Lovinger, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W266, Bethesda, MD 20892,
240–276–6385, lovingeg@mail.nih.gov.
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[USCG–2015–0751]
Cook Inlet Regional Citizen’s Advisory
Council (CIRCAC) Charter Renewal
Coast Guard, DHS.
Notice of recertification.
AGENCY:
ACTION:
SUMMARY: The purpose of this notice is
to inform the public that the Coast
Guard has recertified the Cook Inlet
Regional Citizen’s Advisory Council
(CIRCAC) as an alternative voluntary
advisory group for Cook Inlet, Alaska.
This certification allows the CIRCAC to
monitor the activities of terminal
facilities and crude oil tankers under the
Cook Inlet Program established by
statute.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
This recertification is effective
for the period from September 1, 2015
through August 31, 2016.
FOR FURTHER INFORMATION CONTACT:
LTJG Katharine Martorelli, Seventeenth
Coast Guard District (dpi), by phone at
(907) 463–2809, email
Katharine.E.Martorelli@uscg.mil or by
mail at P.O. Box 25517, Juneau, Alaska
99802.
SUPPLEMENTARY INFORMATION:
DATES:
Background and Purpose
As part of the Oil Pollution Act of
1990, Congress passed the Oil Terminal
and Oil Tanker Environmental
Oversight and Monitoring Act of 1990
(the Act), 33 U.S.C. 2732, to foster a
long-term partnership among industry,
government, and local communities in
overseeing compliance with
environmental concerns in the
operation of crude oil terminals and oil
tankers.
On October 18, 1991, the President
delegated his authority under 33 U.S.C
2732 (o) to the Secretary of
Transportation in Executive Order
12777, section 8(g) (see 56 FR 54757;
October 22, 1991) for purposes of
certifying advisory councils, or groups,
subject to the Act. On March 3, 1992,
the Secretary re-delegated that authority
to the Commandant of the USCG (see 57
FR 8582; March 11, 1992). The
Commandant re-delegated that authority
to the Chief, Office of Marine Safety,
Security and Environmental Protection
(G–M) on March 19, 1992 (letter #5402).
On July 7, 1993, the USCG published
a policy statement, 58 FR 36504, to
clarify the factors that shall be
considered in making the determination
as to whether advisory councils, or
groups, should be certified in
accordance with the Act.
The Assistant Commandant for
Marine Safety and Environmental
Protection (G–M), re-delegated
recertification authority for advisory
councils, or groups, to the Commander,
Seventeenth Coast Guard District on
February 26, 1999 (letter #16450).
On September 16, 2002, the USCG
published a policy statement, 67 FR
58440, that changed the recertification
procedures such that applicants are
required to provide the USCG with
comprehensive information every three
years (triennially). For each of the two
years between the triennial application
procedures, applicants submit a letter
requesting recertification that includes a
description of any substantive changes
to the information provided at the
previous triennial recertification.
Further, public comment is not solicited
prior to recertification during
E:\FR\FM\25SEN1.SGM
25SEN1
]]>Agencies
[Federal Register Volume 80, Number 186 (Friday, September 25, 2015)]
[Notices]
[Pages 57833-57834]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24320]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cell Biology.
Date: October 14, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: John Burch, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institute of Health, 6701
Rockledge Drive, Room 3213, MSC 7808, Bethesda, MD 20892, 301-408-
9519, burchjb@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Clinical Oncology Study Section.
Date: October 19, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Sheraton Reston Hotel, 11810 Sunrise Valley Drive,
Reston, VA 20191.
Contact Person: Malaya Chatterjee, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD
20892, 301-806-2515, chatterm@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Cancer, Cardiovascular and Sleep Epidemiology Panel B Study
Section.
Date: October 19-20, 2015.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Melrose Hotel, 2430 Pennsylvania Avenue NW., Washington,
DC 20037.
Contact Person: Ellen K. Schwartz, EDD, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3144, MSC 7770, Bethesda, MD
20892, 301-828-6146, schwarel@mail.nih.gov.
Name of Committee: Infectious Diseases and Microbiology
Integrated Review Group; Virology--A Study Section.
Date: October 26-27, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Renaissance Washington DC, Dupont Circle, 1143 New
Hampshire Avenue NW., Washington, DC 20037.
Contact Person: Kenneth M. Izumi, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3204, MSC 7808, Bethesda, MD
20892, 301-496-6980, izumikm@csr.nih.gov.
Name of Committee: Immunology Integrated Review Group; Innate
Immunity and Inflammation Study Section.
Date: October 29-30, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites Alexandria-Old Town, 1900 Diagonal Road,
Alexandria, VA 22314.
Contact Person: Tina McIntyre, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4202, MSC 7812, Bethesda, MD 20892, 301-594-
6375, mcintyrt@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Special Topic: Development Functions and Immune Mediated
Diseases.
Date: October 30, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Capital View, 2850 South Potomac Avenue,
Arlington, VA 22202.
Contact Person: Deborah Hodge, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4207 MSC 7812, Bethesda, MD 20892, (301) 435-
1238, hodged@mail.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PARs: Developing and Testing Interventions for Health-
Enhancing Physical Activity.
Date: October 30, 2015.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 57834]]
Place: The Fairmont Washington, DC, 2401 M Street NW.,
Washington, DC 20037.
Contact Person: Weijia Ni, Ph.D., Chief/Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3100, MSC 7808, Bethesda, MD
20892, (301) 594-3292, niw@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Infection, Complement Activation and Inflammatory Immune
Tolerance.
Date: October 30, 2015.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Bahiru Gametchu, DVM, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4204, MSC 7812, Bethesda, MD
20892, 301-435-1225, gametchb@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: September 21, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-24320 Filed 9-24-15; 8:45 am]
BILLING CODE 4140-01-P
